On February 8, 2026, Innovent Biologics and Eli Lilly and Company announced a strategic collaboration to develop new drugs in the field of oncology and immunology[1]. This is the seventh collaboration between the two companies, which have maintained a long-term and productive partnership for more than 10 years[1]. Under the agreement, Innovent will lead drug development from initial concept to clinical evidence of efficacy (completion of phase 2 clinical trials) in China[1]. Eli Lilly will obtain an exclusive license to develop and commercialize these drugs in the global market outside of Greater China, while Innovent retains the rights in this area[1]. This collaboration represents a new model that combines Innovent's discovery and early development capabilities with the global reach and capacity of Eli Lilly[1]. The goal of the partnership is to accelerate the global development of innovative medicines and provide world-renowned medical solutions to patients with cancer and immune system disorders[1].